MGMaura Griffin

Maura Griffin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maura Griffin has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Subclinical Atherosclerosis Risk Can Be Predicted in Female Patients With Systemic Lupus Erythematosus Using Metabolomic Signatures: An Observational Study

    by Laurel Woodridge, Maria G. Tektonidou, George A. Robinson, Junjie Peng, Leda Coelewij, Lucia Martin‐Gutierrez, Elvira Chocano Navarro, Maura Griffin, Andrew Nicolaides, Coziana Ciurtin, et al.

    Background: Cardiovascular disease (CVD) is a leading cause of death in women with systemic lupus erythematosus (SLE) due to accelerated atherosclerosis that is not predicted by established CVD risk scores. This study aimed to develop, validate, and test a female‐focused predictive atherosclerosis risk signature based on serum metabolites in patients with SLE. Methods and Results: Female patients with SLE were assessed for the presence (SLE‐P; n=18) or absence (SLE‐NP; n=26) of subclinical atherosclerosis using vascular ultrasound for carotid/femoral intima‐media thickness. CVD risk was assessed using QRISK3 (which includes SLE diagnosis as a risk factor) and Framingham Risk Score. Serum metabolomics (n≥250) was performed and analyzed using machine learning pipelines. Despite having subclinical atherosclerosis, 44.8% to 100% of patients with SLE‐P had low CVD risk according to QRISK3/Framlingham Risk Score scores. Using a lipid‐focused metabolomic analysis, an improved atherosclerosis risk predictive signature was developed comprising 35 metabolites/5 clinical traits that classified patients with SLE‐P and outperformed CVD risk assessment tools, lipid profiles measured in routine care, and clinical features alone. This “atherosclerosis risk signature” was validated in a second adult female SLE cohort (n=98) that predicted plaque status with moderate accuracy (area under the receiver operating characteristic curve, 0.79). The signature was then refined into a 5‐feature subclinical plaque‐predictive score that not only stratified the combined SLE‐P/SLE‐NP cohorts (n=142; area under the receiver operating characteristic curve, 0.84) but also predicted 3‐year atherosclerosis progression in female postpubertal patients with juvenile‐onset SLE (n=36; area under the receiver operating characteristic curve, 0.79). Finally, the 5‐feature score identified distinct high and low subclinical atherosclerosis risk subgroups in a “real‐world” setting of unscanned adult patients with SLE (n=38). Conclusions: This atherosclerosis risk score could improve CVD risk assessment/management in female patients with SLE across age. Validation in non‐SLE and healthy cohorts could further substantiate these findings.


  • Assessing the impact of ultrasound image standardization in deep learning-based segmentation of carotid plaque types

    by Georgia D. Liapi, Christos P. Loizou, Constantinos S. Pattichis, Marios S. Pattichis, Andrew N. Nicolaides, Maura Griffin, Efthyvoulos Kyriacou


  • Open Access

    Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus

    by Leda Coelewij, Kirsty E. Waddington, George A. Robinson, Elvira Chocano, Thomas McDonnell, Filipa Farinha, Junjie Peng, Pierre Dönnes, Edward Smith, Sara Croca, et al.

    Objective: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing cardiovascular disease. Standard serum lipid measurements in clinical practice do not predict cardiovascular disease risk in patients with SLE. More detailed analysis of lipoprotein taxonomy could identify better predictors of cardiovascular disease risk in SLE. Approach and Results: Eighty women with SLE and no history of cardiovascular disease underwent carotid and femoral ultrasound scans; 30 had atherosclerosis plaques (patients with SLE with subclinical plaque) and 50 had no plaques (patients with SLE with no subclinical plaque). Serum samples obtained at the time of the scan were analyzed using a lipoprotein-focused metabolomics platform assessing 228 metabolites by nuclear magnetic resonance spectroscopy. Data were analyzed using logistic regression and 5 binary classification models with 10-fold cross validation. Patients with SLE had global changes in complex lipoprotein profiles compared with healthy controls despite having clinical serum lipid levels within normal ranges. In the SLE cohort, univariate logistic regression identified 4 metabolites associated with subclinical plaque; 3 subclasses of VLDL (very low-density lipoprotein; free cholesterol in medium and large VLDL particles and phospholipids in chylomicrons and extremely large VLDL particles) and leucine. Together with age, these metabolites were also within the top features identified by the lasso logistic regression (with and without interactions) and random forest machine learning models. Logistic regression with interactions differentiated between patients with SLE with subclinical plaque and patients with SLE with no subclinical plaque groups with the greatest accuracy (0.800). Notably, free cholesterol in large VLDL particles and age differentiated between patients with SLE with subclinical plaque and patients with SLE with no subclinical plaque in all models. Conclusions: Serum metabolites are promising biomarkers to uncover and predict multimetabolic phenotypes of subclinical atherosclerosis in SLE.


  • HR (Paroven, Venoruton; 0-(β-hydroxyethyl)-rutosides) in Venous Hypertensive Microangiopathy: A Prospective, Placebo-Controlled, Randomized Trial

    by L. Incandela, G. Belcaro, S. Renton, M. T. DeSanctis, M. R. Cesarone, P. Bavera, E. Ippolito, M. Bucci, M. Griffin, G. Geroulakos, et al.

    The aim of this study was to demonstrate whether HR (Paroven-Venoruton; 0-(β-hydroxyethyl)-rutosides), was effective in improving the microcirculation in venous hypertension and microangiopathy. Sixty patients with severe venous hypertension due to chronic venous insufficiency, ankle swelling, and lipodermatosclerosis were included. After informed consent, patients were randomized into a treatment group and a placebo group. Patients in the treatment group received oral HR (2 g/day for 8 weeks); those in the placebo group received a comparable placebo. Results: The two groups were comparable for age and sex distribution. The mean age was 45 years (SD 9) in the treatment group (31 patients) and 45.5 (SD 10) in the placebo group (29 patients). There were no differences between the placebo and treatment groups at inclusion. There was no change between inclusion and measurements at 8 weeks in the placebo group. A significant decrease (P < 0.05) in flux at rest and rate of ankle swelling was observed in the treatment group. The decrease in capillary filtration was associated with improvement in signs and symptoms (P < 0.05). The difference in flux, sign and symptoms, and filtration was clinically important at 8 weeks in the treatment group when compared with the placebo group. No adverse effects were observed. Conclusion: Venous microangiopathy was improved by HR treatment.


  • Microvascular Changes in Venous Hypertension due to Varicose Veins After Standardized Application of Essaven Gel

    by M.R. Cesarone, M.T. De Sanctis, L. Incandela, G. Belcaro, M. Griffin

    The involvement of the microvascular structure in chronic venous insufficiency (CVI) causes venous hypertensive microangiopathy (VHM), which leads to venous ulceration. VHM is char acterized by enlarged and ramified capillaries, increased flux and capillary permeability, edema, and altered function of microlymphatics. TcPO2 is decreased and CO2 increased. This perfu sional paradox is caused by hyperperfusion in the deep skin layers with hypoperfusion of superficial nutritional capillaries. Exchanges in the capillary bed are altered. Nutritional skin alterations eventually lead to venous ulceration. Edema is the consequence of increased capillary pressure, reduced clearance, and by an increased exchange surface of capillaries. The aim of this randomized, placebo-controlled study was to evaluate the effect of local treatment with Essaven gel (EG) in 22 subjects with VHM due to severe varicose veins, treated with a single application. Measurements of flux, PO2 and PCO2 in standardized conditions of applica tion indicated a significant decrease of the abnormally increased flux and CO2; PO2 increased in the treatment group. Essaven gel, in comparison with placebo and controls acutely improves the microcirculation in VHM even with a single application.


  • Microcirculatory Effects of Total Triterpenic Fraction of Centella asiatica in Chronic Venous Hypertension: Measurement by Laser Doppler, TcPo 2 -co 2 , and Leg Volumetry

    by M. R. Cesarone, G. Belcaro, A. Rulo, M. Griffin, A. Ricci, E. Ippolito, M. T. De Sanctis, L. Incandela, P. Bavera, M. Cacchio, et al.

    The aim of this prospective, randomized study was to demonstrate whether an oral preparation of TTFCA was effective in improving the microcirculation and edema (leg volume) in venous microangiopathy. Forty patients with venous hypertension were included. Treatment was prescribed for 6 weeks (tablets, 60 mg twice daily). Patients were randomized into a treatment and a placebo group. There were 20 patients in each group. In the treatment group the mean age was 42 (SD 7; M:F = 10:10); in the placebo group, the mean age was 40 (SD 9; M:F = 10:10). Tolerability and compliance were very good; there were no dropouts. At inclusion there were no differences between placebo and treatment group. After treatment there was a decrease in resting flux (29%) and an improvement (increase) in venoarteriolar response (52%); PO 2 was increased (7.2%) and PCO 2 decreased (9.6%). There was an important decrease in leg volume (66 mL decrease; 1.3% volume variation). The difference in flux, O 2 -CO 2 and volume parameters were significant and clinically important at 6 weeks in the treatment group. In conclusion, TTFCA improves microcirculation and leg volume in venous hypertension. The effects of TTFCA are observed even in a limited sample of patients.


  • Grading Internal Carotid Artery Stenosis Using B-mode Ultrasound( Study)

    by S Jmor, T El-Atrozy, M Griffin, T Tegos, S Danjhl, A Nicolaides


  • Ultrasonic plaque character and outcome after lower limb angioplasty

    by Ganesh Ramaswami, Thomas Tegos, Andrew N. Nicolaides, Surinder Dhanjil, Maura Griffin, Aghiad Al-Kutoubi, Gianni Belcaro, John Lewis, Robert Wilkins, Michael J. Davies